Table 1. Relationship between clinical features and miR-20a-5p or Smad4 protein expression in 544 colon cancer patients.
| miR-20a-5p expression | p* | Smad4 expression | p* | |||
|---|---|---|---|---|---|---|
| Low (n = 137) | High (n = 407) | Low (n = 381) | High(n = 163) | |||
| Age | ||||||
| < 65 | 54 (39.4) | 154 (37.8) | 0.761 | 144 (37.8) | 64 (39.3) | 0.773 |
| ≥ 65 | 83 (60.6) | 253 (62.2) | 237 (62.2) | 99 (60.7) | ||
| Gender | ||||||
| Female | 37 (53.3) | 207 (50.9) | 0.693 | 198 (52.0) | 82 (50.3) | 0.779 |
| Male | 64 (46.7) | 200 (49.1) | 183 (48.0) | 81 (49.7) | ||
| Location | ||||||
| Right | 37 (27.0) | 87 (21.4) | 0.280 | 82 (21.5) | 42 (25.8) | 0.124 |
| Transverse | 9 (6.6) | 24 (5.9) | 19 (5.0) | 14 (8.6) | ||
| Left | 91 (66.4) | 296 (72.7) | 280 (73.5) | 107 (65.7) | ||
| pT stage | ||||||
| T1–2 | 38 (27.7) | 79 (19.4) | 0.035* | 68 (17.9) | 49 (30.1) | 0.004* |
| T3–4 | 99 (72.3) | 328 (80.6) | 313 (72.1) | 114 (70.0) | ||
| pN stage | ||||||
| N0 | 93 (67.9) | 221 (54.3) | 0.001* | 209 (54.9) | 105 (64.4) | 0.006* |
| N1–2 | 44 (32.1) | 186 (45.7) | 172 (45.1) | 58 (35.6) | ||
| pM stage | ||||||
| M0 | 133 (97.1) | 371 (91.2) | 0.022* | 347 (91.1) | 157 (96.3) | 0.032 |
| M1 | 4 (2.9) | 36 (8.8) | 34 (8.9) | 6 (3.7) | ||
| AJCC stage | ||||||
| I–II | 91 (66.4) | 210 (51.6) | 0.005* | 198 (52.0) | 103 (63.2) | 0.044* |
| III–IV | 46 (33.6) | 197 (49.4) | 183 (48.0) | 60 (36.8) | ||
| Differentiation | ||||||
| Well | 37 (27.0) | 79 (19.4) | 0.022* | 76 (19.9) | 40 (24.5) | 0.255 |
| Moderate | 86 (62.8) | 250 (61.4) | 235 (61.7) | 101 (62.0) | ||
| Poor | 14 (10.2) | 78 (19.2) | 70 (18.4) | 22 (13.5) | ||
| Smad4 | ||||||
| Negative | 24 (17.5) | 357 (87.7) | < 0.001* | |||
| Positive | 113 (82.5) | 50 (12.3) | ||||
*
p < 0.05 indicates a significant relationship among the variables;
AJCC, American Joint Committee on Cancer.